Avantor Investor Conference Presentation Deck

Bioscience Production ED REVENUE ~$2.3B 2023E RECURRING REVENUE ~95% ADJ. OPERATING MARGIN ~26% 2023E TOTAL ADDRESSABLE MARKET (TAM) $30B+ 2023E revenue based on midpoint of FY 2023 guidance, as of Q3 2023 earnings call. Segment financials based on management estimates for FY 2023. Effective date for the new segment structure is 1/1/24. Recurring revenue excludes equipment & instrumentation. TAM based on management estimates. Leader in high-purity materials for regulated markets Innovation focus supports healthy growth outlook High-margin, recurring, spec'd-in revenue avantor™ 13

View entire presentation